CVRx, Inc. (NASDAQ:CVRX) Position Decreased by Emerald Advisers LLC

Emerald Advisers LLC lessened its stake in CVRx, Inc. (NASDAQ:CVRX - Free Report) by 10.9% in the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 403,054 shares of the company's stock after selling 49,505 shares during the period. Emerald Advisers LLC owned about 1.87% of CVRx worth $3,551,000 at the end of the most recent reporting period.

Other institutional investors have also recently added to or reduced their stakes in the company. Johnson & Johnson lifted its holdings in CVRx by 17.4% during the 1st quarter. Johnson & Johnson now owns 4,103,430 shares of the company's stock worth $74,723,000 after buying an additional 607,855 shares during the last quarter. Vanguard Group Inc. raised its position in shares of CVRx by 5.6% during the 1st quarter. Vanguard Group Inc. now owns 594,312 shares of the company's stock valued at $10,822,000 after acquiring an additional 31,720 shares in the last quarter. Silvercrest Asset Management Group LLC lifted its stake in CVRx by 70.7% during the first quarter. Silvercrest Asset Management Group LLC now owns 253,968 shares of the company's stock worth $4,625,000 after purchasing an additional 105,198 shares during the last quarter. FourWorld Capital Management LLC acquired a new position in CVRx in the first quarter worth $374,000. Finally, Bank of New York Mellon Corp increased its stake in CVRx by 30.7% during the second quarter. Bank of New York Mellon Corp now owns 37,191 shares of the company's stock valued at $446,000 after purchasing an additional 8,741 shares during the last quarter. 75.27% of the stock is owned by institutional investors and hedge funds.

CVRx Stock Performance

CVRX traded up $1.65 during trading hours on Monday, hitting $15.05. The company's stock had a trading volume of 1,247,517 shares, compared to its average volume of 277,453. The company has a 50-day simple moving average of $9.25 and a 200 day simple moving average of $9.49. The company has a current ratio of 10.08, a quick ratio of 8.85 and a debt-to-equity ratio of 0.53. The firm has a market capitalization of $327.88 million, a PE ratio of -5.57 and a beta of 1.15. CVRx, Inc. has a fifty-two week low of $6.40 and a fifty-two week high of $33.13.

CVRx (NASDAQ:CVRX - Get Free Report) last issued its quarterly earnings data on Tuesday, October 29th. The company reported ($0.57) earnings per share for the quarter, missing analysts' consensus estimates of ($0.45) by ($0.12). The company had revenue of $13.37 million for the quarter, compared to the consensus estimate of $13.28 million. CVRx had a negative net margin of 123.75% and a negative return on equity of 88.85%. During the same quarter in the prior year, the firm earned ($0.43) earnings per share. As a group, sell-side analysts expect that CVRx, Inc. will post -2.59 EPS for the current year.

Analyst Upgrades and Downgrades

CVRX has been the topic of a number of recent research reports. Cantor Fitzgerald restated an "overweight" rating and issued a $14.00 price target on shares of CVRx in a research report on Wednesday, October 23rd. Craig Hallum raised their target price on shares of CVRx from $15.00 to $20.00 and gave the stock a "buy" rating in a report on Monday. Lake Street Capital upped their target price on CVRx from $12.00 to $15.00 and gave the company a "buy" rating in a report on Wednesday, October 30th. Canaccord Genuity Group increased their price target on CVRx from $15.00 to $17.00 and gave the stock a "buy" rating in a research report on Wednesday, October 30th. Finally, Piper Sandler restated an "overweight" rating and set a $16.00 price objective (up previously from $13.00) on shares of CVRx in a research report on Wednesday, October 30th. Two analysts have rated the stock with a hold rating and five have issued a buy rating to the company. According to data from MarketBeat, the company presently has an average rating of "Moderate Buy" and an average price target of $15.83.

CVRx Company Profile

CVRx, Inc, a commercial-stage medical device company, focuses on developing, manufacturing, and commercializing neuromodulation solutions for patients with cardiovascular diseases. The company offers Barostim, a neuromodulation device indicated to improve symptoms for patients with heart failure with reduced ejection fraction or systolic heart failure.